Clamídia e HIV: Entendendo o Aumento de Risco em Mulheres e Estratégias de Prevenção

Women with untreated chlamydia (Chlamydia trachomatis) face a two- to threefold higher risk of acquiring HIV from an infected partner compared to those without the infection. This biological synergy significantly drives HIV epidemics, especially in regions with high STI prevalence.

Biological Mechanisms Linking Chlamydia to HIV Susceptibility

• Mucosal barrier disruption: Chlamydia infects columnar epithelial cells, causing inflammation, ulceration, and friability that create physical entry points for HIV.
• Immune cell recruitment: The infection draws CD4+ T cells, macrophages, and dendritic cells—primary HIV targets—into the genital mucosa.
• Inflammatory milieu: Elevated cytokines such as TNF-α, IL-1β, IL-6, and IL-8 enhance HIV replication locally.
• Increased viral shedding: In HIV-positive partners, chlamydia coinfection raises genital HIV shedding, boosting transmission potential.
• Epithelial integrity loss: Disruption of tight junctions allows paracellular HIV translocation across the mucosa.

Epidemiologic Evidence

• Meta-analyses (e.g., McClelland et al., AIDS 2007) show pooled relative risks of 2.0–3.5 for HIV acquisition associated with HSV-2, syphilis, chlamydia, gonorrhea, trichomoniasis, and bacterial vaginosis.
• Chlamydia’s high prevalence and frequent asymptomatic course prolong the window of exposure.
• Population-attributable fraction estimates indicate that STIs account for a substantial proportion of new HIV infections in generalized epidemics.

Clinical and Public Health Implications

• Screen and treat: Annual chlamydia screening for sexually active women under 25 and older women with risk factors (per CDC and USPSTF guidelines).
• Expedited partner therapy (EPT): Reduces reinfection rates by treating partners without requiring a clinical visit.
• Integrated services: Combine STI testing, HIV counseling, and PrEP provision in a single visit.
• PrEP (pre-exposure prophylaxis): Tenofovir/emtricitabine for high-risk women; an STI diagnosis should trigger PrEP consideration.
• Condom promotion: Dual protection against both STIs and HIV.

Public Health Impact

STI control is a structural HIV prevention strategy. Modeling suggests that treating curable STIs could avert 10–30% of new HIV infections in high-burden settings. Integrating STI and HIV services is cost-effective and amplifies the impact of both programs.